Sponsor

ACADIA Pharmaceuticals Inc.

Clinical research sponsor

Published trials33
Recruiting shown3
Roles2
SourceClinicalTrials.gov

Clinical trials

33 shown
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant ResponseNCT07284667 · lead sponsor · 2025-11-14
RECRUITING
ACP-204 in Adults With Alzheimer's Disease PsychosisNCT06159673 · lead sponsor · 2023-11-14
RECRUITING
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension StudyNCT06194799 · lead sponsor · 2024-04-23
ENROLLING_BY_INVITATION
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of SchizophreniaNCT04531982 · lead sponsor · 2020-08-05
COMPLETED
Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease PsychosisNCT04292223 · lead sponsor · 2020-02-10
COMPLETED
Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose QuetiapineNCT04164758 · lead sponsor · 2019-10-23
TERMINATED
Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant TreatmentNCT04000009 · lead sponsor · 2019-06-06
TERMINATED
Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant TreatmentNCT03968159 · lead sponsor · 2019-04-25
COMPLETED
Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and DepressionNCT03482882 · lead sponsor · 2018-03-09
COMPLETED
Relapse Prevention Study of Pimavanserin in Dementia-related PsychosisNCT03325556 · lead sponsor · 2017-09-27
COMPLETED
The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) StudyNCT03152292 · lead sponsor · 2017-03-30
TERMINATED
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's DiseaseNCT03118947 · lead sponsor · 2017-02-23
COMPLETED
Extension Study of Pimavanserin for the Adjunctive Treatment of SchizophreniaNCT03121586 · lead sponsor · 2017-01-01
TERMINATED
Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)NCT03018340 · lead sponsor · 2016-12-01
COMPLETED
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)NCT02970305 · lead sponsor · 2016-11-04
COMPLETED
Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)NCT02992132 · lead sponsor · 2016-11-01
TERMINATED
Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)NCT02970292 · lead sponsor · 2016-10-26
COMPLETED
A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease PsychosisNCT02035553 · lead sponsor · 2013-11-01
COMPLETED
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease PsychosisNCT01174004 · lead sponsor · 2010-07-01
COMPLETED
A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease PsychosisNCT00658567 · lead sponsor · 2008-03-01
COMPLETED
A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease PsychosisNCT00550238 · lead sponsor · 2007-07-01
COMPLETED
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease PsychosisNCT00477672 · lead sponsor · 2007-06-01
COMPLETED
ACP-104 in Acutely Psychotic Subjects With SchizophreniaNCT00490516 · lead sponsor · 2007-06-01
COMPLETED
Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and RisperidoneNCT00361166 · lead sponsor · 2005-08-01
COMPLETED
An Open-label Safety Study of Pimavanserin in Parkinson's Disease PatientsNCT01518309 · lead sponsor · 2004-11-17
COMPLETED
Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational DrugNCT00087542 · lead sponsor · 2004-03-01
COMPLETED
Expanded Access of Pimavanserin for Patients With PD PsychosisNCT02762591 · lead sponsor
APPROVED_FOR_MARKETING
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative DiseasesNCT05357612 · collaborator · 2023-01-23
RECRUITING
The Sub-Sero StudyNCT03994965 · collaborator · 2024-12-01
WITHDRAWN
Pimavanserin for Sleep in Parkinson DiseaseNCT05796167 · collaborator · 2023-01-27
WITHDRAWN
Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.NCT03947216 · collaborator · 2020-10-23
COMPLETED
Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)NCT05240339 · collaborator · 2019-04-25
COMPLETED
Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and PharmacokineticsNCT00628420 · collaborator · 2005-01-01
COMPLETED

Sponsor roles

lead sponsor27
collaborator6

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.